Genetic studies in hydatidiform mole with clinical correlations

Area of Science:

• Reproductive Medicine
• Gynecologic Oncology
• Human Genetics

Background:

• Hydatidiform mole is a gestational trophoblastic neoplasia.
• Pathological classification distinguishes partial mole (PHM) from complete mole (CHM).
• Genetic underpinnings of mole subtypes require further elucidation.

Purpose of the Study:

• To genetically characterize partial mole (PHM) and complete mole (CHM) subtypes.
• To investigate the genetic basis of CHM heterogeneity.
• To correlate genetic subtypes of CHM with clinical outcomes, specifically the need for chemotherapy.

Main Methods:

• Pathological classification of 163 hydatidiform moles into PHM (38) and CHM (125).
• Karyotyping and genetic analysis to determine chromosomal complements.
• Clinical follow-up to assess the incidence of post-mole trophoblastic tumors requiring chemotherapy.

Main Results:

• PHM were triploid (one maternal, two paternal sets); all resolved spontaneously.
• CHM were diploid, subdivided into homozygous androgenetic (46,XX) and heterozygous androgenetic (usually 46,XY) types.
• Frequency of heterozygous CHM was 10%. Chemotherapy was required for 17.6% of CHM patients; no significant difference in chemotherapy need between homozygous (17.8%) and heterozygous (25%) CHM.

Conclusions:

• Genetic analysis provides a robust classification for hydatidiform moles.
• Complete moles can be genetically distinguished into homozygous and heterozygous androgenetic subtypes.
• These genetic subtypes of CHM do not appear to significantly influence the risk of developing post-mole trophoblastic tumors requiring chemotherapy.